MedTrace Logo

Endothelin-Receptor Blockade in Coronary Heart Disease

NCT00427232 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2007-01-26

No results posted yet for this study

Summary

Endothelin is a hormon that causes acute and chronic narrowing of heart vessels. The purpose of this study is to assess whether suppression of this activity by using two types of receptor antagonists can reduce this effect and thus improve blood supply of the heart muscle.

Conditions

  • Coronary Vessels
  • Endothelins
  • Vascular Resistance

Interventions

DRUG

BQ-123 and BQ-788

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Thomas Neunteufl, MD · Dept. of Internal Medicine II, Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Completion
2006-08-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00427232 on ClinicalTrials.gov